Fig. 1: Commercial anti-FcγRI antibodies cannot specifically block ligand binding. | Nature Communications

Fig. 1: Commercial anti-FcγRI antibodies cannot specifically block ligand binding.

From: Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responses

Fig. 1

a Expression of FcγRI on different cell lines. Ba/F3-FcγRI (solid line) or EL4-FcγRI (dashed line) cells without antibody are depicted as the control. b Binding titration of anti-FcγRI antibodies to Ba/F3-FcγRI (solid lines) and EL4-FcγRI (dashed lines) cells. Mean fluorescence intensity (MFI) is depicted of at least N = 3. c Blocking of ligand (hIgG1) on Ba/F3-FcγRI (solid lines) and EL4-FcγRI (dashed lines) cells with different anti-FcγRI antibodies; 197 (circle, dark green), 10.1 (upside down triangle, blue), m22 (triangle, green), H22 (hexagon, green), and mIgG2c (square, yellow). Percentage (%) ligand blocking was calculated using the ligand only as a control. d Bar graphs showing ligand blocking at 10 μg/ml of the indicated antibodies. N = 3, in duplo. Data are mean ± SEM, Two-way ANOVA with Tukey’s post hoc test. Source data are provided as a Source Data file.

Back to article page